Literature DB >> 6730140

Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents.

K D Tew, B Hartley-Asp.   

Abstract

Using cultured HeLa S3 cells an ID50 of 2.5 micrograms/ml was found after a twenty-four-hour incubation with estradiol-17 beta- 3N -bis-(2-chloroethyl) carbamate (estramustine). Similar ID90 values were found in two Walker 256 rat carcinoma cell lines which were either sensitive or resistant to nitrogen mustards. Alkaline elution methodology revealed the complete absence of DNA strand breaks or cross-links in cells receiving up to 10 micrograms/ml estramustine for twenty-four hours. Nuclear uptake was 1.34 per cent of the available drug, one third of which was hydrophobically associated with the protein/phospholipid components of the nuclear matrix. In the human prostatic cell lines DU145 and PC3 , estramustine caused a drastic dose-dependent increase in the mitotic index. This increase resulted from an arrest of cells in metaphase, with highly contracted disoriented chromosomes present. Rapid reverse of the arrest on removal of drug resulted in cell death. Neither nor-nitrogen mustard nor estradiol demonstrated antimitotic properties. The lack of macromolecular alkylation together with the observed antimitotic effects predict a mechanism of action for estramustine which is distinct from either of its constituent components.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6730140     DOI: 10.1016/s0090-4295(84)80094-1

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

1.  Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine.

Authors:  K D Tew; M E Stearns
Journal:  Urol Res       Date:  1987

Review 2.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 3.  Estramustine in malignant glioma.

Authors:  A T Bergenheim; R Henriksson; J M Piepmeier; D Yoshida
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

4.  Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.

Authors:  Christopher V Johnson; Tiffani Shelton; Charles J Smith; Lixin Ma; Michael C Perry; Wynn A Volkert; Timothy J Hoffman
Journal:  Cancer Biother Radiopharm       Date:  2006-04       Impact factor: 3.099

5.  Targeting microtubule-associated proteins in glioblastoma: a new strategy for selective therapy.

Authors:  J M Piepmeier; P E Pedersen; D Yoshida; C Greer
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

6.  Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.

Authors:  Daisaku Hirano; Yusuke Nagane; Katsuhiko Satoh; Junichi Mochida; Shuji Sugimoto; Taketo Ichinose; Satoru Takahashi; Toshiya Maebayashi; Tsutomu Saitoh
Journal:  Int Urol Nephrol       Date:  2009-05-16       Impact factor: 2.370

7.  Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets.

Authors:  M E Stearns; D P Jenkins; K D Tew
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

8.  Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer.

Authors:  F Boccardo; A Decensi; D Guarneri; G Martorana; C Giberti; L Giuliani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.

Authors:  L A Speicher; V R Sheridan; A K Godwin; K D Tew
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.